Pfizer 2012 Annual Report Download - page 118

Download and view the complete annual report

Please find page 118 of the 2012 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 121

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121

Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies
2012 Financial Report
117
Quarter
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) First Second Third Fourth
2012
Revenues $14,885 $15,057 $13,976 $15,068
Costs and expenses(a) 11,853 10,383 10,683 12,107
Restructuring charges and certain acquisition-related costs(b) 597 190 302 791
Income from continuing operations before provision/(benefit) for taxes on income 2,435 4,484 2,991 2,170
Provision/(benefit) for taxes on income 711 1,290 (119)680
Income from continuing operations 1,724 3,194 3,110 1,490
Discontinued operations—net of tax(c) 79 66 104 4,831
Net income before allocation to noncontrolling interests 1,803 3,260 3,214 6,321
Less: Net income attributable to noncontrolling interests 97
66
Net income attributable to Pfizer Inc. $1,794 $3,253 $3,208 $6,315
Earnings per common share—basic:
Income from continuing operations attributable to Pfizer Inc. common
shareholders $0.23 $0.43 $0.42 $0.20
Discontinued operations—net of tax 0.01 0.01 0.01 0.66
Net income attributable to Pfizer Inc. common shareholders $0.24 $0.44 $0.43 $0.86
Earnings per common share—diluted:
Income from continuing operations attributable to Pfizer Inc. common
shareholders $0.23 $0.42 $0.41 $0.20
Discontinued operations—net of tax 0.01 0.01 0.01 0.65
Net income attributable to Pfizer Inc. common shareholders $0.24 $0.43 $0.43 $0.85
Cash dividends paid per common share $0.22 $0.22 $0.22 $0.22
Stock prices
High $22.80 $23.30 $25.15 $26.09
Low $20.75 $21.40 $22.00 $23.55
(a) The fourth quarter of 2012 reflects historically higher Q4 costs in Cost of sales, Selling, informational and administrative expenses, Research and development
expenses and Other deductions—net.
(b) The fourth quarter of 2012 reflects higher employee termination costs.
(c) The fourth quarter of 2012 reflects the gain on the sale of our Nutrition business.
Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may
not agree to the total for the year.
As of January 31, 2013, there were 207,223 holders of record of our common stock (New York Stock Exchange symbol PFE).